Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.
Cornberg M, Hüppe D, Sarrazin C, Ahumada A, Jorquera Plaza F, Mariño Z, Otano JIU, Conway B, Myles L, Ramji A, Abergel A, Asselah T, Larrey D, Aghemo A, Andreoni M, Gasbarrini A, Lampertico P, Persico M, Villa E, Carmiel M, Chodick G, Weil C, Bhagat A, Bondin M, Butrymowicz I, Song Y, Semizarov D, Sonparote S, Llamas C; CREST Study Group.
Cornberg M, et al. Among authors: butrymowicz i.
Adv Ther. 2024 Dec;41(12):4669-4682. doi: 10.1007/s12325-024-02996-6. Epub 2024 Oct 29.
Adv Ther. 2024.
PMID: 39470876